热门资讯> 正文
Crystem Pharmaceuticals宣布拟公开募股3.5亿美元
2026-01-06 05:21
- Crinetics Pharmaceuticals (NASDAQ:CRNX) on Monday stated that they intended an underwritten public offering of $350M of common stock, subject to market and other conditions, with a 30-day underwriters’ option to purchase up to an additional $52.5M of shares.
- The company plans to use the net proceeds, along with existing cash and investments, to support the commercial launch of PALSONIFY™, ongoing research programs, and general corporate purposes, including capital expenditures and working capital.
- The remaining net proceeds would be used for potential in-licensing, acquisition, or investment opportunities involving complementary businesses.
- Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor are acting as joint bookrunning managers for the proposed offering.
- Shares +3.10%.
More on Crinetics Pharmaceuticals
- Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia - Slideshow
- Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript
- Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
- Crinetics plans $350 mln public share offering
- Crinetics outlines 2026 pipeline expansion and targets PALSONIFY as first-line acromegaly therapy
推荐文章
千亿资金需求下 OpenAI本周在ChatGPT上线广告
华盛早报 | 美股、金银全线暴跌，纳指跌超2%！韩国人再度扫货中国股票，大举买入MINIMAX、澜起科技；节前央行1万亿元买断式逆回购来了
美国联邦贸易委员会：苹果新闻偏袒左翼媒体、打压保守派内容
美股机会日报 | 就业数据转弱！美国至2月7日当周初请失业金人数超预期；存储概念股盘前齐升，闪迪大涨超7%
要点速递！《跑赢美股》春节特别直播核心观点总结
道指“一枝独秀”连创新高！特朗普喊话还能翻倍，轮动行情下如何平稳“上车”价值股ETF？
华盛早报 | 非农数据大超预期！首次降息或延至7月；AI恐慌交易蔓延至房地产服务板块， CBRE暴跌12%；智谱发布新模型
美股机会日报 | 经济数据强劲！美国1月非农就业大超预期，纳指期货涨至0.6%；AI应用股业绩超预期，Shopify涨超10%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
